Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Kyoung Sup | - |
dc.contributor.author | Kim, You Sun | - |
dc.contributor.author | Han, Dong Soo | - |
dc.contributor.author | Choi, Chang Hwan | - |
dc.contributor.author | Jang, Byung-Ik | - |
dc.contributor.author | Park, Young-Sook | - |
dc.contributor.author | Lee, Kang-Moon | - |
dc.contributor.author | Lee, Soo Teik | - |
dc.contributor.author | Kim, Hyun-Soo | - |
dc.contributor.author | Kim, Joo Sung | - |
dc.date.accessioned | 2022-12-20T15:59:28Z | - |
dc.date.available | 2022-12-20T15:59:28Z | - |
dc.date.created | 2022-08-26 | - |
dc.date.issued | 2010-09 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/174214 | - |
dc.description.abstract | Background/Aims: Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea. Methods: We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure. Results: Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67% vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups. Conclusions: These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.title | Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Dong Soo | - |
dc.identifier.doi | 10.5009/gnl.2010.4.3.357 | - |
dc.identifier.scopusid | 2-s2.0-77957580225 | - |
dc.identifier.wosid | 000281932300009 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.4, no.3, pp.357 - 362 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 4 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 357 | - |
dc.citation.endPage | 362 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001569424 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | RESISTANT ESCHERICHIA-COLI | - |
dc.subject.keywordPlus | TRAVELERS DIARRHEA | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | BACTERIA | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | EMERGENCE | - |
dc.subject.keywordPlus | KOREA | - |
dc.subject.keywordAuthor | Acute infectious diarrhea | - |
dc.subject.keywordAuthor | Rifaximin | - |
dc.subject.keywordAuthor | Ciprofloxacin | - |
dc.identifier.url | https://www.gutnliver.org/journal/view.html?volume=4&number=3&spage=357&year=2010 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.